Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 38
Semaglutide Grey Market Risks and Quality
Counterfeit Ozempic, compounded semaglutide salt forms, and dosing errors: what regulators have found and what a COA cannot tell you.
Semax Grey Market Risks and Quality Testing
Semax is sold online with no regulatory oversight outside Russia. What COA testing reveals about identity, purity, and contamination.
Tesamorelin Grey Market Risks and Quality
Tesamorelin is FDA-approved only for HIV lipodystrophy. Grey-market vials sold for off-label use carry identity, purity, and contamination risks.
Tirzepatide Grey Market Risks and Quality
Counterfeit Mounjaro pens, compounded tirzepatide after the shortage ended, and FDA recalls: what regulators have found and what a COA cannot tell you.
Semaglutide at 6 months: STEP trial data
Community posts report 80-90 lbs lost in six months on semaglutide. Here is what STEP trial data shows about timelines and plateaus.
Semaglutide in teens: who responds best?
A real-world study asks which adolescents respond best to semaglutide for obesity, moving beyond the STEP TEENS trial into clinical practice.
Semaglutide and beta-cell function in T1D
A 2026 case study reports preserved beta-cell function and stable blood sugar in a newly diagnosed type 1 diabetes patient treated with semaglutide.
Semaglutide cut fentanyl seeking in rats
A 2026 rat study found that single doses of semaglutide prevented cue-, drug- and stress-triggered fentanyl seeking. Human trials are next.
Semaglutide in HFpEF: German cost analysis
A German study finds semaglutide cost-effective for heart failure with preserved ejection fraction and obesity, with a five-year ICER of 30,443 EUR/QALY.
Ketone esters spare muscle on semaglutide
A JCI Insight mouse study finds ketone ester co-treatment preserves skeletal muscle mass during semaglutide therapy without reducing fat loss.
Semaglutide and Alzheimer's: EVOKE review
A new paper revisits the EVOKE trials and finds limited semaglutide signals at later timepoints, despite the primary endpoint failure at two years.
Semaglutide weight loss: the trial data
STEP 5 shows 15% average weight loss sustained at two years. What the data says about body composition, eating behaviour, and stopping.